Back to search results

Prehabilitation for Ovarian and Pancreatic Cancer with Chemotherapy

This study is looking at whether a special exercise and nutrition program, called prehabilitation, can help older adults (65 and over) with advanced ovarian, fallopian tube, primary peritoneal, or pancreatic cancer who are receiving chemotherapy before surgery. The prehabilitation involves using SmartGyms, bands, or smartphones to guide exercise sessions on TechnoGym equipment. The main goal is to see how well participants stick to this exercise and nutrition program over 6 weeks. We don't know the current recruitment status, but the study plans to enroll 22 people. This study aims to understand if prehabilitation can improve physical fitness, surgical outcomes, nutrition, and quality of life compared to standard care.

Study design
This is an interventional study with a planned enrollment of 22 participants. The study does not specify a phase.
What's involved
Participants will engage in a multimodal prehabilitation intervention, which includes an exercise program using specific gym equipment and guidance.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, adherence, is measured at 6 weeks post intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06412510

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

Recruiting
PHASE1Ages 65+InterventionalSupportive care
Case Comprehensive Cancer Center
~22 participants
Updated 2026-03-18 on ClinicalTrials.gov
What's tested:Prehabilitation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rate of adherence as calculated by the compliance percentage
Measured over 6 weeks post intervention

Conditions

Ovarian Cancer
Epithelial Ovarian Cancer
Pancreatic Adenocarcinoma

Explore related trials

Bladder CarcinomaEsophageal CarcinomaFallopian Tube CarcinomaOvarian CarcinomaPancreatic CarcinomaPrimary Peritoneal Carcinoma

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Mariam AlHilli, MD · PRINCIPAL_INVESTIGATOR · Cleveland Clinic Foundation, Case Comprehensive Cancer Center

Who to contact

Mariam AlHilli, MD
[email protected]
216-644-0418
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 65 and older
Patients with diagnosis of advanced (Stage III or IV) epithelial ovarian, fallopian tube, or
Patients with diagnosis of pancreatic adenocarcinoma (PDAC) (Stage I, II, or III) undergoing neoadjuvant chemotherapy.
Patients with locally advanced esophageal cancer undergoing neoadjuvant chemotherapy.
Patients with locally advanced muscle invasive bladder cancer undergoing neoadjuvant chemotherapy.

Exclusion

Life expectancy less than 3 months in the opinion of the treating physician
Patients unable to provide informed consent.
Wheelchair bound patients/ physical immobility.
Severe cardiopulmonary disease defined as NYHA class III or IV
Patients with malignant bowel obstruction who will require surgical intervention or nutritional support in the form of enteral or parenteral nutrition will also be excluded.
Patients with any other comorbidity or condition, which, in the opinion of the enrolling investigator, would place the patient at unnecessarily higher greater risk or burden, or participating in the study would not be in the best interests of the patient.

What this trial measures

  • Rate of adherence as calculated by the compliance percentage6 weeks post intervention

    Compliance will be defined as completion of at least 2 exercise sessions per week (75%) for the duration of the study.